LSD Statistics Graph: Survey Data, Dosages, and Trends

National survey data from the United States shows that LSD use has been climbing steadily since the early 2000s, with new users entering the population at increasing rates each year. Between 2002 and 2019, about 0.18% of survey participants reported trying LSD for the first time in any given year, with the odds of first-time use rising roughly 8% per additional calendar year. That upward line is not a blip or a single cohort aging into experimentation. It cuts across teenagers, young adults, and people over 26, making it one of the more consistent drug-trend graphs in recent federal survey history. The data behind that trend, along with what we know about dosages, demographics, and risks, paints a detailed and sometimes surprising picture.

The Upward Trend in U.S. Use

The most comprehensive dataset tracking LSD use over time comes from the National Survey on Drug Use and Health (NSDUH), an annual federally funded household survey. An analysis of NSDUH data from 2002 to 2019 found that LSD use increased across every age group measured. Among 18- to 25-year-olds, the increase was steepest, with a prevalence difference of about 3.1 percentage points over that span. Adolescents aged 12 to 17 and adults 26 and older also showed statistically significant increases, though the absolute numbers were smaller.¹ First-time LSD initiation followed a similar trajectory, with the year-over-year odds of someone trying LSD for the first time growing at a consistent clip throughout the study period.²

A separate analysis covering 2015 to 2018 reported a roughly 56% increase in LSD use over just that four-year window, suggesting the trend may have accelerated in the latter half of the decade.³ This period overlaps with a growing cultural conversation around psychedelics, increased media coverage of clinical research, and a shift in how younger adults in particular view the risk profile of these substances.

The current trend stands in contrast to the early 1990s, when LSD use among high schoolers was already drawing attention. A 1993 survey of over half a million junior and senior high school students found hallucinogen use at about 5.3%, up from 4.9% the year before.⁴ That earlier wave eventually subsided through the late 1990s and early 2000s before the current, slower-building increase took hold.

Who Uses LSD

Demographics of past-year LSD users look quite different from the general population. A study using NSDUH data from 2015 to 2019 found that compared with non-users, LSD users were disproportionately male (about 68% versus 48%), young adults aged 18 to 25 (56% versus 12%), and white (71% versus 63%). They were far more likely to be never-married (86% versus 28%), to have no children under 18 at home (93% versus 73%), and to identify as lesbian, gay, or bisexual (18% versus 5%). LSD users also skewed toward lower income brackets, with about a quarter earning less than $20,000 a year, and were more likely to be unemployed or working part-time.⁵

That profile makes LSD use look like a young, urban, economically precarious phenomenon, though it is worth noting the NSDUH captures all past-year use without distinguishing a single experience from regular consumption. The survey also undercounts populations not living in traditional households, meaning it likely misses some users on both ends of the socioeconomic spectrum.

What the Dosage Data Actually Shows

One of the areas where controlled research has become increasingly precise is dose-response mapping. A placebo-controlled study that tested LSD at 100 and 200 micrograms found that both doses produced strong subjective effects, but the higher dose drove significantly greater ego dissolution, impaired sense of control, and anxiety compared with the lower one.⁶ A broader dose-response analysis found that most subjective effects follow a sigmoid-shaped curve, rising steeply through lower doses and flattening out or plateauing around 100 micrograms. Scales measuring anxiety and dread of ego dissolution, however, kept climbing in a more linear fashion even at higher doses, meaning the unpleasant effects don’t level off the way the positive ones do.⁷

This finding matters for understanding real-world risk. If you double the dose from 100 to 200 micrograms, you are not doubling the visual or emotional intensity of the experience in a proportional way. What you are doing, disproportionately, is increasing anxiety and loss of control. The psychedelic “ceiling” for pleasurable effects arrives earlier than the ceiling for distressing ones.

At the other end of the spectrum, a controlled microdosing study tested LSD at 6.5, 13, and 26 micrograms in healthy volunteers. Effects were dose-related but subtle. At 26 micrograms, participants reported increased vigor and slightly altered emotional responses to images, but cognition, mood on most measures, and physiological markers like heart rate and blood pressure were unaffected.⁸ The gap between a microdose and a full psychedelic experience is enormous in pharmacological terms, something that gets lost in popular media where the two are sometimes discussed as if they sit on a smooth continuum.

Microdosing by the Numbers

Microdosing has become one of the most talked-about aspects of psychedelic culture, and recent surveys are starting to put hard numbers on it. A nationally representative U.S. survey found that about 4.8% of American adults reported microdosing LSD, translating to an estimated 12.4 million people. Psilocybin was slightly more commonly microdosed at 5.3%, and cannabis led the list at 9.4%. Crucially, the motivations differ by substance. Cannabis microdosing was primarily medical, with about 41% of cannabis microdosers doing it for pain management. But LSD microdosing was mostly recreational: roughly 59% of LSD microdosers said their primary reason was something like wanting to get less high, rather than treating a health condition.⁹

That finding clashes somewhat with the narrative that has built up around microdosing in wellness culture, where it is frequently framed as a mental health intervention. An earlier international survey of people who self-identified as microdosers found that about 40% were motivated by mental health improvement, 31% by personal development, and 18% by cognitive enhancement.¹⁰ The difference likely reflects who gets sampled: a self-selected online community of microdosing enthusiasts skews toward wellness motivations, while a nationally representative probability sample captures the broader spectrum of people who have ever taken a small dose, including casual experimenters.

State-level policy is now catching up. An increasing number of U.S. states are implementing or considering alternatives to outright prohibition of some psychedelic substances for non-clinical use, which is prompting new data collection on microdosing prevalence and patterns.¹¹

Global Patterns and Regional Differences

LSD is not solely an American phenomenon, and looking at international data reveals that usage patterns vary in interesting ways by region. The Global Psychedelic Survey, which analyzed over 6,300 responses from 85 countries, found that psilocybin, LSD, and MDMA were the three most commonly used psychedelics across all regions studied, including North America, Europe and the UK, and Australia and New Zealand. But the details diverged. Microdosing was more prevalent among North American respondents. Frequency of use tended to be lower in Australia and New Zealand. Motivations also split by region: therapeutic use was less commonly reported in Europe and the UK compared with North America, suggesting that the “psychedelic therapy” framing that dominates American discourse has not fully translated across the Atlantic.¹²

Personal growth was the most common motivation across all regions, which complicates the clean division between “recreational” and “therapeutic” use that surveys try to impose. For many users, a full-dose LSD experience is neither purely fun nor purely medicinal but sits somewhere in between.

Challenging Experiences and Emergency Data

One question that anyone looking at LSD trend data inevitably asks is whether rising use has meant rising harms. The answer is layered. A large survey of psychedelic users found that about 41% had experienced at least one challenging, difficult, or distressing episode while using classic psychedelics. LSD was the substance most commonly associated with these experiences: 24% of all respondents, or about 32% of people who had ever used LSD specifically, reported one. Yet the same survey found that a majority of respondents, even those who reported enduring symptoms like anxiety afterward, agreed with the statement that they were glad they had used classic psychedelics.¹³

First-time users tell a more optimistic story in aggregate. A Global Drug Survey analysis of over 3,300 people who used LSD in the past year found that first-time experiences generally exceeded expectations, with nearly 98% expressing excitement about the experience. Feelings of fear were reported by most respondents (about 64%), but were typically described as mild and not enough to discourage future use. Only 17 individuals in the entire sample needed emergency medical attention.¹⁴

U.S. poison center data gives a more clinical picture. Between 2000 and 2016, poison centers logged 3,554 LSD exposures. The overwhelming majority of patients were between 13 and 29, and about 74% were male. The most common effects were agitation (42%), rapid heart rate (39%), and hallucinations (37%). Serious complications were rare but included hyperthermia, seizures, coma, and cardiac arrest. Most patients were treated and released from the emergency department, though LSD cases were admitted to critical care units more often than psilocybin mushroom cases.¹⁵

Hallucinogen Persisting Perception Disorder

One risk that does not appear in emergency department statistics but generates significant concern is hallucinogen persisting perception disorder, or HPPD. This is a condition in which visual disturbances from a psychedelic experience recur long after the drug has left the body, sometimes weeks or months later. It is considered rare, and the medical literature on it consists mostly of case reports rather than large epidemiological studies, which makes estimating its true prevalence difficult.¹⁶ Online communities of people who experience HPPD are vocal and growing, which may reflect either a genuine increase tied to rising LSD use or simply greater awareness and willingness to discuss the condition publicly. The lack of systematic data makes it impossible to distinguish between the two.

The Purity Problem

A significant confound in interpreting any real-world LSD data is that what people think they are taking is not always what they actually get. Drug-checking services at a major European music festival tested samples that users believed to be LSD and found that only about 67% contained LSD alone. About a quarter of samples contained no LSD at all but did contain another psychoactive substance. Among the adulterants, the most common were dimethoxyamphetamine derivatives (about 11%) and NBOMe compounds (about 10%), both of which carry a substantially higher risk of serious physical harm than LSD itself. Another 8% of samples contained no detectable psychoactive substance whatsoever.¹⁷

This matters enormously when reading any survey that relies on self-report. When a person says they used LSD and then reports their dose, their adverse effects, or their motivations, there is a non-trivial chance that they consumed something else entirely. NBOMe compounds in particular have been linked to deaths at doses that LSD would survive, meaning that some emergency presentations attributed to “LSD” in both media reports and poison center data may actually involve a different and more dangerous substance. Drug-checking services and reagent testing kits have expanded in availability but remain far from universal.

What Combination Use Looks Like

LSD does not exist in a pharmacological vacuum. An analysis of online drug discussion forums mapped the network of substances people commonly combined and found that LSD serves as a central hub connecting several clusters. On one side, it bridges to MDMA and amphetamine-related compounds, a combination colloquially known as “candyflipping.” On the other, it connects to anticholinergic substances like those found in jimson weed.¹⁸ The popularity of these combinations complicates any effort to attribute specific outcomes to LSD alone. When emergency departments see a patient who says they took LSD and presents with unusual symptoms, the explanation may involve polydrug use, an adulterant, or both.

Clinical Trial Data and the Therapeutic Picture

The rising public interest in LSD has been matched by a resurgence in clinical research. Recent controlled trials are producing some of the first rigorous efficacy data since the substance was banned from research in the late 1960s. A phase II trial in patients with anxiety, some of whom had life-threatening illnesses, found that two sessions of LSD-assisted therapy produced large reductions in anxiety and depression scores that remained significant at 16 weeks. The effect size for anxiety was large, and positive acute experiences during the sessions correlated with better long-term outcomes. Only about 19% of participants reported mild acute side effects, and one serious adverse event, acute transient anxiety, was recorded in the entire trial.¹⁹

A 12-month follow-up of participants from that same research group found that the anxiety and depression reductions persisted, with large effect sizes still evident a year after the study visits ended.²⁰ These are small trials, and the durability of benefits beyond one year remains an open question.

In major depression, the results have been more equivocal. A randomized trial comparing high-dose LSD-assisted therapy against low-dose LSD as a control found a clinically meaningful difference on one of two primary depression scales, but the other scale narrowly missed statistical significance. Response rates were roughly double in the high-dose group (about 40-44%) compared with the low-dose group (20%), and remission rates followed a similar pattern.²¹ The mixed statistical picture here is a reminder that early-phase trial results in psychiatry often look more dramatic than what holds up in larger confirmatory studies. The data is genuinely promising but not yet settled.

Law Enforcement Seizure Data

Survey data tells one side of the story. Law enforcement seizures tell another. Compared with substances like cannabis, cocaine, or methamphetamine, LSD represents a tiny fraction of what police confiscate. In Norway, for example, LSD seizures accounted for about 1% of all drug seizures in 2019, totaling roughly 13,000 user doses. The low seizure volume reflects several realities: LSD is active at microgram quantities, meaning a lifetime supply for one person fits on a few small squares of paper; it is odorless and nearly weightless; and it does not generate the visible supply-chain infrastructure that bulkier drugs do. This makes LSD inherently harder to interdict than most other controlled substances, which in turn means seizure statistics likely underrepresent actual circulation far more than they do for drugs like heroin or cocaine.

The discrepancy between rising survey-reported use and relatively flat seizure numbers is often cited as evidence that enforcement tools are poorly calibrated to LSD’s physical profile. Whether that gap will widen as use continues to climb is an open question that drug policy analysts are watching closely.